A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: Preliminary report

S. Lastoria, P. D'amico, L. Mansi, G. G. Giordano, R. Rossiello, J. Schlom, E. Pace, N. Panza, G. Pacilio, M. Salvatore

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85% in the detection of primary ovarian cancers and collections of ascites, and of 84% in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.

Original languageEnglish
Pages (from-to)347-356
Number of pages10
JournalNuclear Medicine Communications
Volume9
Issue number5
Publication statusPublished - 1988

Fingerprint

Monoclonal Antibodies
Prospective Studies
Ascites
Ovarian Neoplasms
Ovary
X Ray Computed Tomography
Cross Reactions
Intravenous Injections
Iodine
Adenocarcinoma
B72.3 antibody
Ovarian epithelial cancer
Neoplasm Metastasis
Antigens
Antibodies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer : Preliminary report. / Lastoria, S.; D'amico, P.; Mansi, L.; Giordano, G. G.; Rossiello, R.; Schlom, J.; Pace, E.; Panza, N.; Pacilio, G.; Salvatore, M.

In: Nuclear Medicine Communications, Vol. 9, No. 5, 1988, p. 347-356.

Research output: Contribution to journalArticle

Lastoria, S, D'amico, P, Mansi, L, Giordano, GG, Rossiello, R, Schlom, J, Pace, E, Panza, N, Pacilio, G & Salvatore, M 1988, 'A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: Preliminary report', Nuclear Medicine Communications, vol. 9, no. 5, pp. 347-356.
Lastoria, S. ; D'amico, P. ; Mansi, L. ; Giordano, G. G. ; Rossiello, R. ; Schlom, J. ; Pace, E. ; Panza, N. ; Pacilio, G. ; Salvatore, M. / A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer : Preliminary report. In: Nuclear Medicine Communications. 1988 ; Vol. 9, No. 5. pp. 347-356.
@article{1a89fbeeff63417a81014da04e211005,
title = "A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: Preliminary report",
abstract = "Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85{\%} in the detection of primary ovarian cancers and collections of ascites, and of 84{\%} in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.",
author = "S. Lastoria and P. D'amico and L. Mansi and Giordano, {G. G.} and R. Rossiello and J. Schlom and E. Pace and N. Panza and G. Pacilio and M. Salvatore",
year = "1988",
language = "English",
volume = "9",
pages = "347--356",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer

T2 - Preliminary report

AU - Lastoria, S.

AU - D'amico, P.

AU - Mansi, L.

AU - Giordano, G. G.

AU - Rossiello, R.

AU - Schlom, J.

AU - Pace, E.

AU - Panza, N.

AU - Pacilio, G.

AU - Salvatore, M.

PY - 1988

Y1 - 1988

N2 - Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85% in the detection of primary ovarian cancers and collections of ascites, and of 84% in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.

AB - Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85% in the detection of primary ovarian cancers and collections of ascites, and of 84% in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.

UR - http://www.scopus.com/inward/record.url?scp=0023928487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023928487&partnerID=8YFLogxK

M3 - Article

C2 - 2842708

AN - SCOPUS:0023928487

VL - 9

SP - 347

EP - 356

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 5

ER -